Adicet Bio to Host Webcast Presentation of ADI-001 Interim Clinical Data in B Cell Non-Hodgkin’s Lymphoma
Adicet Bio, Inc. (ACET)
Last adicet bio, inc. earnings: 5/3 05:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
aceto.com/ir/index.html
Company Research
Source: GlobeNewswire
ADI-001 is the first ever allogeneic, off-the-shelf, gamma delta CAR T cell therapy to report clinical data Event to be webcast on December 6, 2021 at 8:30 a.m. EST MENLO PARK, Calif. and BOSTON, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the Company will host a webcast presentation on Monday, December 6, 2021 at 8:30 AM EST to discuss interim data from its dose escalation Phase 1 study evaluating the safety and tolerability of ADI-001, Adicet’s investigational first-in-class allogeneic gamma delta CAR T cell therapy targeting CD20 for the potential treatment of B Cell Non-Hodgkin’s Lymphoma. The event will feature Sattva S. Neelapu, M.D., Professor in the Department of Lymphoma-Myeloma at The University of Texas MD Anderson Cancer Center, alongside members of the Adicet management team. Conference C
Show less
Read more
Impact Snapshot
Event Time:
ACET
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACET alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACET alerts
High impacting Adicet Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ACET
News
- Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual ConferenceBusiness Wire
- Adicet Bio, Inc. (NASDAQ: ACET) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
- Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Adicet Bio (ACET) Loses -16.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]Yahoo! Finance
ACET
Earnings
- 3/19/24 - Beat
ACET
Sec Filings
- 4/12/24 - Form PRE
- 3/22/24 - Form 8-K
- 3/22/24 - Form 424B5
- ACET's page on the SEC website